New nonalcoholic beer crafted specifically for cancer patients

Michael Walter | | Radiology Business | Practice Management

A new beer being served in the Czech Republic was crafted with a very specific audience in mind: cancer patients undergoing chemotherapy.

The beverage, called Mamma Beer, is nonalcoholic, according to a report from NPR. It is meant to counteract dysgeusia, a common side effect of chemotherapy that ruins the taste of most food and drinks. The team behind Mamma Beer is also involved with Mamma HELP, a nonprofit breast cancer advocacy group in the Czech Republic.

"Chemotherapy in breast cancer patients often causes a loss in taste or a change of taste that leads to a lower intake of nutrients than patients need during their treatment," said Karolina Hovorkova, MD, as quoted by NPR. Hovorkova has been serving samples of the drink to her patients in Prague since April.

Click below to read the full story.

Czech Company Designs A Nonalcoholic Beer To Taste Good To Cancer Patients

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

US Radiology Specialists affiliate expands into new market
Navigating the radiology workforce shortage: 6 potential solutions
Radiologist rails against insurer’s refusal to cover key interventional service
Blue Cross Blue Shield affiliate rejects MRI contrast coverage, labeling it ‘investigational’
Radiology experts say state Medicaid rates must increase to improve imaging access
Can large language models break language barriers in radiology reports?

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.